LETTERS The authors respond to “Adverse health outcomes in transgender people” We thank Dr. Townsend and colleagues for their letter1 in response to our article.2 It is regrettable that the authors feel our report perpetuates inequity in the care of transgender people. The focus of our report was to review the evidence for estrogen as a thrombotic risk factor, while also guiding colleagues to some readily accessible educational materials that may prove helpful in the care of transgender people. In writing the case, we took advice from the patient, transgender people and health care specialists. Our goal was to help physicians and patients in similar situations, as they work together to optimize health. We’re on the same side here and appreciate their comments.



Martina A. Kelly MBBCh MA Associate Professor, Department of Family Medicine, University of Calgary Cumming School of Medicine Calgary, Alta. Wesley Chan MD MSc Resident, Department of Opthalmology and Visual Sciences, Faculty of Medicine, Dalhousie University, Halifax, NS Alasdair Drummond MBChB Physician, Stettler Medical Clinic, Stettler, Alta. n Cite as: CMAJ 2017 August 14;189:E1047. doi: 10.1503/cmaj.733300

References 1.

2.

Townsend M, Jaffer H, Goldman L. Adverse health outcomes in transgender people [letter]. CMAJ 2017;189:E1046. Chan W, Drummond A, Kelly M. Deep vein thrombosis in a transgender woman. CMAJ 2017;189:E502-4.

Competing interests: None declared.

CMAJ | AUGUST 14, 2017 | VOLUME 189 | ISSUE 32

E1047